<?xml version="1.0" encoding="UTF-8"?>
<ref id="B110-pharmaceuticals-12-00060">
 <label>110.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Pires De Mello</surname>
    <given-names>C.P.</given-names>
   </name>
   <name>
    <surname>Tao</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>T.H.</given-names>
   </name>
   <name>
    <surname>Bulitta</surname>
    <given-names>J.B.</given-names>
   </name>
   <name>
    <surname>Rodriquez</surname>
    <given-names>J.L.</given-names>
   </name>
   <name>
    <surname>Pomeroy</surname>
    <given-names>J.J.</given-names>
   </name>
   <name>
    <surname>Brown</surname>
    <given-names>A.N.</given-names>
   </name>
  </person-group>
  <article-title>Zika virus replication is substantially inhibited by novel favipiravir and interferon alpha combination regimens</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <year>2018</year>
  <volume>62</volume>
  <fpage>e01983-17</fpage>
  <pub-id pub-id-type="doi">10.1128/AAC.01983-17</pub-id>
  <?supplied-pmid 29109164?>
  <pub-id pub-id-type="pmid">29109164</pub-id>
 </element-citation>
</ref>
